Abstract 1601P
Background
Sarcopenia is a common condition among cancer patients. The aim of this study is to investigate the potential relationship between sarcopenia and hematologic toxicity in cancer patients by evaluating skeletal muscles with computed tomography (CT) and ultrasound (US) before chemotherapy.
Methods
A prospective cohort study was conducted on cancer patients who received anthracycline-based chemotherapy between 2018 and 2020 and had baseline abdominal CT containing L3 level for measuring skeletal muscle index (L3 SMI) and/or muscle US were included. Sex-specific cut-offs for L3 SMI were used for diagnosis of sarcopenia. Sex- and body mass index–adjusted sonographic thigh adjustment ratio (STAR) values (cut-off values 1.0 for female patients and 1.4 for male patients) were used for US assessment of sarcopenia.
Results
A total of 65 patients (14 male, 51 female) were included; 40 (61.5%) with breast cancer, 17 (26.2%) with lymphoma, and 8 (12.3%) with sarcoma. Mean age was 46.3 ± 14 years. Sarcopenia was determined in 13 patients (20%) according to CT, and in 10 patients (15.4%) according to US assessment. Regarding acute toxicity, patients with sarcopenia according to CT L3-SMI value had a significantly higher incidence of grade ≥ 3 neutropenia (39% vs 12%, p = 0.045) but similar level of thrombocytopenia (%3 vs %0, p > 0.9) after the first cycle of chemotherapy compared to non-sarcopenic patients. Patients with sarcopenia based on STAR values also had a significantly higher incidence of grade ≥ 3 neutropenia (50% vs 16%, p = 0.03) and higher incidence of grade ≥ 3 thrombocytopenia (10% vs 0%, p = 0.15) after the first cycle of chemotherapy compared to non-sarcopenic patients.
Conclusions
We found a significant association between sarcopenia diagnosed by CT and US and hematologic toxicity. Routine CT scans performed for cancer staging may help clinicians identify high-risk patients and facilitate closer monitoring of side effects and earlier introduction of supportive measures. US based assessment of sarcopenia also has high diagnostic accuracy and may predict neutropenia risk. US may serve as an easy-to-use, point of care tool for assessing sarcopenia with the advantage of repeated sequential assessment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1605P - The impact of cancer pain on survival of lung cancer patients receiving immune checkpoint inhibitors
Presenter: Sichao Wang
Session: Poster session 05
1606P - Sarcopenia, depression, and modes of feeding among cancer patients
Presenter: Muhammad Khokhar
Session: Poster session 05
1607P - Patient perceptions of the efficacy, safety, and quality of the evidence available on medicinal cannabis: A survey of Australian cancer patients - comparing users to non-users
Presenter: Joseph Taylor
Session: Poster session 05
1608P - Albumin-myosteatosis gauge as a prognostic factor in patients with advanced pancreatic cancer undergoing first-line chemotherapy
Presenter: Omer Dizdar
Session: Poster session 05
1609P - A machine learning-based prognostic model to predict survival in patients with advanced cancer admitted to an acute palliative care unit
Presenter: Eun Hee Jung
Session: Poster session 05
1610P - A new updated prognostic index for patients with brain metastases (BM) treated with palliative whole brain radiotherapy (WBRT) in the era of precision oncology: METASNCore project
Presenter: Pablo Flores Paco
Session: Poster session 05
1611P - Family carers’ experiences with brain metastases: A longitudinal qualitative study
Presenter: Tonje Lundeby
Session: Poster session 05
1612P - Demonstrating the complexity of need and the effectiveness of integrated palliative care: An analysis of routinely collected patient centred outcome measures
Presenter: Joanne Hayes
Session: Poster session 05
1613P - The BreakThrough cancer malnutrition
Presenter: Stefano De Santis
Session: Poster session 05
1614P - Integrated palliative care for patients referred for Chimeric Antigen Receptor T-cell (CAR-T) therapy: A service evaluation
Presenter: Rebekah Williams
Session: Poster session 05